Well, Scholar Rock holding on to gain since reporting that his spinal muscular atrophy drug helped patients on Eli Liy Zeppbound reduce muscle loss, a known risk factor tied to GLP1 obesity drugs. The drug is still in mid-stage trials for weight loss, but currently under FDA priority review to treat SMA, a genetic muscle wasting disease. Joining us now to dig into the results is Scholar Rock CEO David Halal.David, great to have you with us. Great to be with you, Melissa. Um, so walk us through the data beca ...

Scholar Rock SRRK revealed results on Wednesday from the Phase 2 EMBRAZE proof-of-concept trial assessing apitegromab in combination with tirzepatide to preserve lean mass during tirzepatide-induced weight loss.Tirzepatide is an active ingredient in Eli Lilly And Co’s LLY widely used Mounjaro and Zepbound for diabetes and weight loss, respectively.The trial demonstrated that 30% of the total weight loss with tirzepatide alone was due to lean mass loss.Apitegromab therapy (10 mg/kg) with tripeptide preserved ...